Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 251 - 275 of 14347 in total
Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal secretion....
Approved
Matched Description: … and combination hormone replacement therapy generally offers no therapeutic advantage. ... It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in ... It is now known that the thyroid gland secretes approximately ten times more T4 than T3 and that 80% …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Approved
Experimental
Investigational
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is...
Approved
Investigational
Matched Description: … Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Cytotoxic Antibiotics and Related Substances …
Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates. Intravenous formulation was approved in Europe in September 2010 as Brinavess and...
Approved
Investigational
Matched Description: … Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April …
Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a...
Approved
Investigational
Matched Description: … associated with Parkinson's disease , pure autonomic failure, and multiple system atrophy, and is the ... It is approved for use in Japan and is currently in trials in the U.S. ... The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated …
Matched Categories: … Epinephrine and similars ... Adrenergic and Dopaminergic Agents ... Amino Acids, Peptides, and Proteins …
Hydroxyamphetamine is a derivative of amphetamines. Hydroxyamphetamine is intended mainly as local eye drops for diagnostic purposes. It is indirect sympathomimetic agent which cause dilation of the eye pupil before diagnostic test. Among the minor side effects from its use are: change in color vision, difficulty seeing at night, dry...
Approved
Matched Description: … night, dry mouth, headache, increased sensitivity of eyes to sunlight, muscle stiffness or tightness and
Levomethamphetamine, the L-enantiomer of methamphetamine is a sympathomimetic vasoconstrictor used in some over-the-counter (OTC) nasal decongestant inhalers in the United States.
Approved
Phenyl salicylate is a 2-hydroxybenzoic acid phenyl ester. It is utilized in some manufacturing processes of polymers, lacquers, adhesives, waxes, as well as polishes. It is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in DB00945 ). Phenyl salicylate may...
Approved
Matched Description: … This compound belongs to the class of organic compounds known as depsides and depsidones. …
Matched Categories: … Genito Urinary System and Sex Hormones ... Miscellaneous Analgesics and Antipyretics …
Elbasvir is a direct-acting antiviral medication used as part of combination therapy to treat chronic hepatitis C, an infectious liver disease caused by infection with hepatitis C virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in...
Approved
Matched Description: … for genotype 1 and 97% and 100% for genotype 4 after 12 weeks of treatment. ... achieve a sustained virologic response (SVR), and have been shown to achieve a SVR between 94% and 97% ... Elbasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly. …
Matched Categories: … elbasvir and grazoprevir …
Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has...
Approved
Matched Description: … onset of action and well tolerated profile in both local and systemic setting [A18805]. ... It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist ... It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Gestrinone, also known as ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group that is marketed in Europe, Australia, and Latin America, though not the United States or Canada, and is used primarily in the treatment of endometriosis. Gestrinone was developed in the early 1970s and was tested clinically as...
Approved
Matched Description: … in Europe and North America. ... Gestrinone was developed in the early 1970s and was tested clinically as a weekly oral contraceptive ... Without significant advantages over other oral contraceptives and with its high cost, gestrinone was …
Matched Categories: … Antigonadotropins and Similar Agents ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Naturally or synthetically produced steroid estrogens have a wide range of pharmaceutical uses ranging from hormonal contraception to the treatment of menopausal symptoms. Estetrol (E4) is a native estrogen occurring naturally during pregnancy, but can be synthesized from a plant source and used for contraception. It is more potent and...
Approved
Investigational
Matched Description: … a native estrogen occurring naturally during pregnancy, but can be synthesized from a plant source and ... [L33179] It is more potent and is safer than the synthetic estrogen ethinylestradiol (EE2) found in 97% ... [L33184] On April 15 2021, Mayne Pharma Group Limited and Mithra Pharmaceuticals were granted FDA …
Matched Categories: … drospirenone and estetrol ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Pnb has been used in trials studying the treatment of Pelvic Organ Prolapse.
Approved
Experimental
Investigational
Oxetacaine, also called oxethazaince, is a potent surface analgesic with the molecular formula N, N-bis-(N-methyl-N-phenyl-t-butyl-acetamide)-beta-hydroxyethylamine that conserves its unionized form at low pH levels. Its actions have shown to relieve dysphagia, relieve pain due to reflux, chronic gastritis, and duodenal ulcer. Oxetacaine is approved by Health Canada since 1995 for...
Approved
Investigational
Matched Description: … Its actions have shown to relieve dysphagia, relieve pain due to reflux, chronic gastritis, and duodenal …
Matched Categories: … Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use …
Sparsentan is a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II (Ang II) type 1 receptor (AT1R) with a similar affinity for both (9.3 nM for ETAR and 0.8 nM for AT1R).[A257330,L45300] Sparsentan is first in its class and orally active, and was created by...
Approved
Investigational
Matched Description: … [A257330,L45300] Sparsentan is first in its class and orally active, and was created by merging the structural ... Sparsentan is a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin ... [L45315] The use of sparsentan may cause hepatotoxicity and embryo-fetal toxicity.[L45300] …
Parthenolide has been used in trials studying the diagnostic of Allergic Contact Dermatitis.
Approved
Investigational
Fluticasone is a synthetic glucocorticoid available as 2 esters, DB08906 and DB00588[F4355,F4358,F4361,F4364][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358,F4361,F4364][FDA Label]. DB00588 was first approved in 1990 and DB08906 was approved in 2007 .
Approved
Experimental
Matched Description: … [DB00588] was first approved in 1990[L5962] and [DB08906] was approved in 2007[L5965]. ... Fluticasone is a synthetic glucocorticoid available as 2 esters, [DB08906] and [DB00588][F4355,F4358, ... These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory …
Matched Categories: … formoterol and fluticasone ... salmeterol and fluticasone …
Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA...
Approved
Investigational
Matched Description: … and proliferation. ... IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth ... [A248750] Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.
Approved
Investigational
Matched Categories: … Antiglaucoma Preparations and Miotics …
Heart failure is a multifactorial condition that affects roughly 1-2% of the adult population. Often the result of long-term myocardial ischemia, cardiomyopathy, or other cardiac insults, heart failure results from an inability of the heart to perfuse peripheral tissues with sufficient oxygen and metabolites, resulting in complex systemic pathologies. Heart...
Approved
Matched Description: … and peripheral vasodilation in acute decongested heart failure. ... failure results from an inability of the heart to perfuse peripheral tissues with sufficient oxygen and ... cyclic adenosine monophosphate (cAMP) production, which affects the heart's contractile function and
A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.
Approved
Illicit
Vet approved
Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of...
Approved
Matched Description: … antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and ... The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the ... mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.
Approved
Matched Description: … It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid …
Penicillamine is a pharmaceutical of the chelator class. The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine). It is an α-amino acid metabolite of penicillin, although it has no antibiotic properties.
Approved
Matched Categories: … Amino Acids, Peptides, and Proteins ... Penicillamine and Similar Agents ... Antiinflammatory and Antirheumatic Products …
Displaying drugs 251 - 275 of 14347 in total